Concentration of fractional excretion of nitric oxide (FENO): A potential airway biomarker of restored CFTR function

BackgroundLower airway biomarkers of restored cystic fibrosis transmembrane conductance regulator (CFTR) function are limited. We hypothesized that fractional excretion of nitric oxide (FENO), typically low in CF patients, would demonstrate reproducibility during CFTR-independent therapies, and increase during CFTR-specific intervention (ivacaftor) in patients with CFTR gating mutations.MethodsRepeated FENO and spirometry measurements in children with CF (Cohort 1; n = 29) were performed during hospital admission for acute pulmonary exacerbations and routine outpatient care. FENO measurements before and after one month of ivacaftor treatment (150 mg every 12 h) were completed in CF patients with CFTR gating mutations (Cohort 2; n = 5).ResultsCohort 1: Mean forced expiratory volume in 1 s (FEV1 % predicted) at enrollment was 72.3% (range 25%-102%). Mean FENO measurements varied minimally over the two inpatient and two outpatient measurements (9.8-10.9 ppb). There were no clear changes related to treatment of pulmonary exacerbations, gender, genotype or microbiology, and weak correlation with inhaled corticosteroid use (P < 0.05). Between the two inpatient measurements, FEV1 % predicted increased by 7.3% (P < 0.03) and FENO did not change. In Cohort 2, mean FENO increased from 6.6 ppb (SD = 2.19) to 11.8 ppb (SD = 4.97) during ivacaftor treatment. Mean sweat chloride dropped by 58 mM and mean FEV1 % predicted increased by 10.2%.ConclusionsRepeated FENO measurements were stable in CF patients, whereas FENO increased in all patients with CFTR gating mutations treated with ivacaftor. Acute changes in FENO may serve as a biomarker of restored CFTR function in the CF lower airway during CFTR modulator treatment.